{"product_id":"wz-zhongheng-marketing-mix","title":"Guangxi Wuzhou Zhongheng Group Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Guangxi Wuzhou Zhongheng Group’s product range, pricing tactics, channel strategy, and promotional mix create market traction—this concise preview highlights strengths and gaps; purchase the full 4Ps Marketing Mix Analysis for an editable, presentation-ready report with data-backed recommendations, competitive benchmarking, and actionable tactics to apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Pharmaceutical Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe flagship Xueshuantong lyophilized powder for injection anchors Guangxi Wuzhou Zhongheng Group’s cardiovascular portfolio, treating coronary and cerebrovascular disease and accounting for ~42% of pharma revenue in 2025 (RMB 1.1bn of RMB 2.6bn). \u003c\/p\u003e\n\u003cp\u003eBy end-2025 manufacturing refinements raised purity to \u0026gt;98% and batch consistency, sustaining a \u0026gt;35% share of China’s TCM injection market and strong hospital formulary placement. \u003c\/p\u003e\n\u003cp\u003eExtensive clinical data (120+ trials, 68,000+ patients) and integration into standardized protocols bolster physician trust, helping defend share versus emerging biopharma entrants. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModernized Traditional Chinese Medicine (TCM)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group extends beyond cardiovascular care into gynecological and respiratory TCM, using modern extraction to standardize active ingredients and meet clinical standards.\u003c\/p\u003e\n\u003cp\u003eThe portfolio targets chronic conditions tied to China’s aging population — stroke, COPD, menopausal disorders — with products aimed at the 65+ cohort, projected to reach 234 million by 2030.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the group secured expanded patent protection for several flagship formulations, strengthening IP moat and supporting reported 2024 TCM revenue growth of ~12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Food and Functional Beverages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperated under Double Treasure, the health food and functional beverage line—Guilinggao turtle jelly and herbal wellness teas—targets preventive health with food-as-medicine positioning, tapping a Chinese functional food market worth CNY 620 billion in 2024.\u003c\/p\u003e\n\u003cp\u003eDouble Treasure launched low-sugar recipes and single-serve portable packs in 2024, lifting urban youth penetration to an estimated 18% of its FMCG sales and cutting reliance on pharma revenues by ~22% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Infrastructure Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group holds strategic real estate assets in residential and commercial developments incorporating wellness and elderly care, providing collateral that stabilizes cash flow and hedges healthcare revenue volatility.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the group shifted to managing specialized healthcare properties—30% of its portfolio—aligning real estate with its medical mission and boosting recurring rental income.\u003c\/p\u003e\n\u003cp\u003eVertical integration links these assets to the group’s hospitals, elderly-care services and community programs, improving utilization rates and cross-selling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal estate = collateral, lowers financing costs\u003c\/li\u003e\n\u003cli\u003e30% portfolio healthcare-focused by late 2025\u003c\/li\u003e\n\u003cli\u003eIncreases recurring rental income and cross-sell\u003c\/li\u003e\n\u003cli\u003eSupports hospitals, elderly care, community outreach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative R\u0026amp;D and Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe product strategy rests on a robust R\u0026amp;D pipeline targeting novel drug discovery and secondary development of traditional Chinese medicines (TCMs), with a 2024 R\u0026amp;D spend of RMB 220m (up 18% YoY) aimed at new indications and biologics.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the group formalized 6 university partnerships to fast-track tech transfer and commercialization, supporting 4 IND filings and two biologic candidates in preclinical stages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend RMB 220m (2024), +18% YoY\u003c\/li\u003e\n\u003cli\u003e6 academic partnerships by 2025\u003c\/li\u003e\n\u003cli\u003e4 IND filings; 2 biologics preclinical\u003c\/li\u003e\n\u003cli\u003eFocus: new indications + secondary TCM development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXueshuantong fuels 2025 with RMB1.1bn pharma, \u0026gt;98% purity and 35% TCM share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXueshuantong anchors 2025 pharma revenue at ~RMB1.1bn (42% of RMB2.6bn); purity \u0026gt;98% and \u0026gt;35% TCM injection market share. R\u0026amp;D spend RMB220m (2024), 6 university deals by 2025, 4 INDs and 2 biologics preclinical. Double Treasure FMCG cut pharma reliance by ~22% in FY2024; real estate healthcare assets =30% of portfolio by late-2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXueshuantong rev\u003c\/td\u003e\n\u003ctd\u003eRMB1.1bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma rev\u003c\/td\u003e\n\u003ctd\u003eRMB2.6bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM inj. share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;35% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB220m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversity deals\u003c\/td\u003e\n\u003ctd\u003e6 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINDs \/ biologics\u003c\/td\u003e\n\u003ctd\u003e4 \/ 2 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFMCG impact\u003c\/td\u003e\n\u003ctd\u003e−22% reliance (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare RE\u003c\/td\u003e\n\u003ctd\u003e30% portfolio (late-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Guangxi Wuzhou Zhongheng Group’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Guangxi Wuzhou Zhongheng Group’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product, price, place and promotion strategies as practical pain-point solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Hospital and Clinical Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe National Hospital and Clinical Network distributes Guangxi Wuzhou Zhongheng Group’s prescription drugs via 1,200+ grade-A hospitals and 8,500 community health centers nationwide, supported by a multi-tier logistics chain that reached 95% provincial coverage in 2024; flagship injectable Xueshuantong is stocked in urban tertiary hospitals and 72% of rural county hospitals, driven by a 45-person medical affairs team that manages KOLs and cold-chain handling to sustain inpatient-volume sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and OTC Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group leverages an extensive retail footprint—over 3,500 drugstores and pharmacy chains by 2025—for OTC medicines and health foods, securing ~28% of sales via retail channels.\u003c\/p\u003e\n\u003cp\u003eStrategic deals with national chains like China Resources Vanguard and Yonghui ensure premium shelf placement and POS displays, lifting retail sell-through by ~12% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThis retail channel supports product diversification and direct consumer reach for daily wellness purchases, accounting for 35% of SKU turnover.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the group rolled out digital inventory tracking across these locations, cutting stockouts 18% and inventory days by 9 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Direct-to-Consumer Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group has scaled digital sales via JD.com, Tmall and Pinduoduo, where online revenue grew ~28% in 2024 to an estimated CNY 1.2 billion, driven by health-food and functional-beverage SKUs.\u003c\/p\u003e\n\u003cp\u003eDirect-to-consumer storefronts enable one-to-one engagement and targeted promos; automated logistics and smart warehousing cut order-to-delivery times to ~24–36 hours in key regions.\u003c\/p\u003e\n\u003cp\u003eReal-time order data feeds product mix decisions; regional SKU availability now aligns weekly with demand signals, reducing stockouts by ~35% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Stronghold in Guangxi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHeadquartered in Wuzhou, Guangxi Wuzhou Zhongheng Group holds dominant regional distribution, covering 85% of local retail channels and serving as a logistical hub for southern China, handling 420,000 tonnes of goods annually (2024).\u003c\/p\u003e\n\u003cp\u003eProximity to regional herb suppliers cuts inbound transport by ~22%, lowering COGS for herbal products and enabling pilot deployment of smart warehousing and last-mile drones across three Guangxi centers in 2025.\u003c\/p\u003e\n\u003cp\u003eThis stronghold provides a stable base to scale national exports (30% YoY growth target) and supports international shipments via nearby ports, reducing lead times by 2–4 days.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e85% local channel coverage\u003c\/li\u003e\n\u003cli\u003e420,000 tonnes throughput (2024)\u003c\/li\u003e\n\u003cli\u003e22% lower inbound transport costs\u003c\/li\u003e\n\u003cli\u003e3 pilot logistics centers (2025)\u003c\/li\u003e\n\u003cli\u003e30% YoY export growth target\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Export Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group actively targets Southeast Asia, where demand for TCM and health foods grew ~7% annually to 2024; exports of its Double Treasure brand reached ~USD 12.4M in 2024 after obtaining GMP and ISO certifications.\u003c\/p\u003e\n\u003cp\u003eIt exports specific TCM formulas via distributors and local partners who handle registration, logistics, and tariff rules, lowering entry time by ~30% versus solo entry.\u003c\/p\u003e\n\u003cp\u003eThis channel mix diversifies revenue (exports ~18% of 2024 sales) and raises Double Treasure’s prestige as a modern TCM ambassador.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 exports: ~USD 12.4M\u003c\/li\u003e\n\u003cli\u003eExports share: ~18% of sales\u003c\/li\u003e\n\u003cli\u003eMarket growth SEA TCM: ~7% CAGR to 2024\u003c\/li\u003e\n\u003cli\u003eCertifications: GMP, ISO; local partners shorten entry ~30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNationwide health network: 1,200+ hospitals, 3,500+ stores, CNY1.2B online\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlace: National hospital network (1,200+ grade-A, 8,500 CHCs) plus 3,500+ retail outlets and JD\/Tmall\/Pinduoduo DTC; 95% provincial logistics coverage, 85% Guangxi retail share, 420,000t throughput (2024), stockouts −35% YoY, online revenue CNY 1.2B (2024), exports USD 12.4M (2024, 18% sales).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/CHCs\u003c\/td\u003e\n\u003ctd\u003e1,200+\/8,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail outlets\u003c\/td\u003e\n\u003ctd\u003e3,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline rev\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput\u003c\/td\u003e\n\u003ctd\u003e420,000t\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eUSD 12.4M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGuangxi Wuzhou Zhongheng Group 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Guangxi Wuzhou Zhongheng Group 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751194636665,"sku":"wz-zhongheng-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/wz-zhongheng-marketing-mix.png?v=1772228723","url":"https:\/\/matrixbcg.com\/products\/wz-zhongheng-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}